Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 26, Issue -, Pages 87-95Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2015.10.006
Keywords
-
Categories
Funding
- University of Nebraska Foundation
- Vice Chancellor's office of the University of Nebraska Medical Center for Core Facility Developments
- National Institutes of Health [P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P01 NS43985, P30 MH062261, R01 AG043540]
- Department of Defense [W81XWH11-1-0700]
Ask authors/readers for more resources
While immune control is associated with nigrostriatal neuroprotection for Parkinson's disease, direct cause and effect relationships have not yet been realized, and modulating the immune system for therapeutic gain has been openly debated. Here, we review how innate and adaptive immunity affect disease pathobiology, and how each could be harnessed for treatment. The overarching idea is to employ immunopharmacologics as neuroprotective strategies for disease. The aim of the current work is to review disease modifying treatments that are currently being developed as neuroprotective strategies for PD in experimental animal models and for human disease translation. The long-term goal of this research is to effectively harness the immune system to slow or prevent PD pathobiology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available